Search Results for

Showing 21 - 30 of 523 results
  1. Publications Committee

    Publications Committee Publications Committee Description The Publications Committee (PUBS) provides guidance to ensure the optimal positioning of the Association's journals and makes recommendations to the Board of Trustees as appropriate. The Committee also provides scholarly publishing resources for ARVO members and assists the Board ofTrustees with related policy decisions. Activities Identifies and addresses topics necessary to stay current with scholarly publishing. Reviews the per

  2. Spotlight on members: Spark

    Spotlight on members From hospital funding to FDA approval Spark Therapeutics develops gene therapy for inherited retinal blindness After over two decades of research and development in gene therapy, Katherine A. High, MD, co-founder, president and chief scientific officer of Spark Therapeutics, is breathing a big sigh of relief this fall. On Oct. 12, the Food and Drug Administration unanimously voted to approve voretigene neparvovec, Spark Therapeutics' gene therapy treatment for inherited b

  3. ARVO Education

    ARVO Education Online Education Meet presentations Education Courses

  4. Telling the story of OCT

    Telling the story of OCT Optical coherence tomography (OCT) is a technology invented by ARVO members that helps preserve patients' sight, saves taxpayers billions of dollars and enables further discoveries in science and medicine. See how ARVO has shared the impact of OCT with vision scientists, patients, and policymakers.  OCT projects

  5. ARVO Foundation: Advancing science and careers

    ARVO Foundation Advancing science and careers Genentech AMD Research Fellowship recipients share their progress The Genentech Age-Related Macular Degeneration (AMD) Research Fellowships are awarded annually through the ARVO Foundation. The award supports two research fellowships for young investigators who are age 45 or younger, including one award for basic research in the understanding of AMD and one for translational AMD research focusing on therapeutics (not yet in clinical trials). The

  6. ARVO Foundation welcomes Chair Paul Sternberg, Jr.

    ARVO Foundation ARVO Foundation welcomes new chair Paul Sternberg, Jr. Paul Sternberg, Jr., MD, FARVO, will take the helm of the ARVO Foundation as chair of the Board of Governors in April. Sternberg has served as a Governor since 2014 and is a past ARVO Trustee representing the Retina Section. Sternberg is the G. W. Hale Professor of Ophthalmology at the Vanderbilt Eye Institute and chief medical officer and chief patient experience officer at Vanderbilt University Medical Center in Nashvil

  7. Spotlight on members: ONL Therapeutics

    Spotlight on members ONL Therapeutics: More than a one-shot wonder It’s a classic story: scientist discovers a compound with real therapeutic potential, only to have no idea how to move forward. Fortunately for David Zacks, MD, PhD, professor of ophthalmology and visual sciences at the University of Michigan Kellogg Eye Center, help was waiting on campus. Guided by the university’s technology transfer office, ONL Therapeutics was incorporated. And with Small Business Innovative Research (SBIR

  8. 5 members in 5 minutes

    5 members in 5 minutes Sharing vision research with new audiences Last year, ARVO launched its one-year Science Communication Training Fellowship (SciCommTF) program to train Members-in-Training from the U.S and outside the U.S. to become more effective communicators of vision research to various audiences. As one of their requirements, each fellow is responsible for developing and implementing an advocacy or outreach activity. Are you thinking about how you can share your research with patie

  9. Trending topics: Image interpretation-The next hurdle

    Trending topics Image interpretation: The next hurdle Once upon a time, our ability to image the eye and its structures was not very good. Fundus images were low resolution, optical coherence tomography (OCT) was limited in depth and dimensions and fluorescein angiography was still considered an effective method to image the vascular system despite its laborious and qualitative nature. Then came the 21st Century. Fundus images saw dramatic improvements in quality and clinical value. OCT ad

  10. Advocacy-outreach: ARVO publishes its first study

    Advocacy and outreach ARVO study proves vision research investment saves billions Taking a new step in its mission to increase funding for vision research, ARVO coauthored its first peer-reviewed paper, which quantifies how millions of dollars of investment in developing optical coherence tomography (OCT) has generated billions of dollars in savings for patients with wet age-related macular degeneration (wet AMD) and government-funded healthcare programs The paper, which was made open access